{"organizations": [], "uuid": "bd46e4afa489d669de9b4a6bf8831ebdd86b1efe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180413.html", "section_title": "Archive News &amp; Video for Friday, 13 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kiadis-pharma-fy-net-loss-widens-t/brief-kiadis-pharma-fy-net-loss-widens-to-17-0-million-euros-idUSFWN1RP16N", "country": "US", "domain_rank": 408, "title": "BRIEF-Kiadis Pharma FY Net Loss Widens To 17.0 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.042, "site_type": "news", "published": "2018-04-13T13:10:00.000+03:00", "replies_count": 0, "uuid": "bd46e4afa489d669de9b4a6bf8831ebdd86b1efe"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kiadis-pharma-fy-net-loss-widens-t/brief-kiadis-pharma-fy-net-loss-widens-to-17-0-million-euros-idUSFWN1RP16N", "ord_in_thread": 0, "title": "BRIEF-Kiadis Pharma FY Net Loss Widens To 17.0 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "kiadis pharma nv", "sentiment": "negative"}, {"name": "ecember", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13 (Reuters) - Kiadis Pharma NV:\n* KIADIS PHARMA ANNOUNCES ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017\n* SIGNIFICANTLY STRENGTHENED CASH POSITION; RAISED OVER EUR 60 MILLION IN EQUITY AND DEBT (GROSS, INCLUDING RAISE IN MARCH 2018)\n* FILED MARKETING AUTHORIZATION APPLICATION WITH EUROPEAN MEDICINES AGENCY FOR ATIR101 IN BLOOD CANCERS\n* FY NET LOSS EUR 17.0 MILLION VERSUS LOSS OF EUR 14.8 MILLION YEAR AGO\n* ON TRACK TO OBTAIN A CHMP OPINION IN Q4 OF 2018 FOR OUR LEAD PROGRAM ATIR101\n* FY OPERATING LOSS EUR 16.1 MILLION VERSUS LOSS OF EUR 11.4 MILLION YEAR AGO\n* IF POSITIVE, CHMP OPINION WOULD ENABLE AN APPROVAL FROM EUROPEAN COMMISSION IN Q1 OF 2019\n* CASH POSITION INCREASED TO EUR 29.6 MILLION AT YEAR-END 2017 COMPARED TO EUR 14.6 MILLION AT END OF 2016\n* POTENTIAL LAUNCH OF PROGRAM ATIR101 IN SELECTED COUNTRIES IN EUROPE STARTING IN H2 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T13:10:00.000+03:00", "crawled": "2018-04-14T13:35:27.001+03:00", "highlightTitle": ""}